EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Audeo Oncology's enterprise value is $0.00 Mil.
Audeo Oncology's Revenue for the trailing twelve months (TTM) ended in Sep. 2012 was $0.06 Mil. Therefore, Audeo Oncology's EV-to-Revenue for today is 0.00.
The historical rank and industry rank for Audeo Oncology's EV-to-Revenue or its related term are showing as below:
AURX's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.375 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-14), Audeo Oncology's stock price is $0.00.
Audeo Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00. Therefore, Audeo Oncology's PS Ratio for today is .
Audeo Oncology EV-to-Revenue Historical Data
The historical data trend for Audeo Oncology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Audeo Oncology EV-to-Revenue Chart
Audeo Oncology Annual Data
Trend
Jun10
Jun11
Jun12
EV-to-Revenue
-
-
-
Audeo Oncology Quarterly Data
Jun11
Mar12
Jun12
Sep12
EV-to-Revenue
-
-
-
-
Competitive Comparison of Audeo Oncology's EV-to-Revenue
For the Drug Manufacturers - General subindustry, Audeo Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Audeo Oncology's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Audeo Oncology's EV-to-Revenue falls into.
Audeo Oncology's current Enterprise Value is $0.00 Mil.
Audeo Oncology's Revenue for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Audeo Oncology's share price for today is $0.00.
Audeo Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Audeo Oncology EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Audeo Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Audeo Oncology (Audeo Oncology) Business Description
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DELISTED:AURX has been successfully added to your